Advanced search
Publication Cover
Journal of Chemotherapy Volume 17, 2005 - Issue 1
Submit an article Journal homepage
41
Views
10
CrossRef citations to date
0
Altmetric
Experimental and Clinical Research

Penetration of Amphotericin B in Human Lung Tissue after Single Liposomal Amphotericin B (AmBisome) Infusion

G. Demartini
,
C. Lequaglie
,
P.P. Brega massone
,
F. Scaglione
&
F. Fraschini
Pages 82-85 | Published online: 18 Jul 2013

References

  • Holleran WM, Wilbur JR, De Gregorio MW. Empiric amphotericin B therapy in patients with acute leukemia. Rev Infect Dis 1985; 7: 619–624.
  • Chopra R, Blair S, Strang J, Cervi P, Patterson KG, Goldstone AH. Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J Antimicrob Chemother, 1991; 28 (Suppl. B): 93-104.
  • Heinemann V, Jehn U, Scholz P, et al. AmBisome-pharmacokinetic and clinical results. Bone Marrow Transplant, 1993; 12 (Suppl.): S147-148.
  • Joly V, Saint-Julien L, Carbon C, Yeni P. Interactions of free and liposomal amphotericin B with renal proximal tubular cells in primary culture. J Pharmacol Exp Ther 1990; 255: 17–22.
  • Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B (AmBisome): safety data from a phaseclinicaltrial. J Antimicrob Chemother, 1991; 28 (Suppl. B): 83-91.
  • Lequaglie C, Giudice G, Brega Massone PP, Cataldo I. Antifungal therapy in thoracic cancer patients with low dose liposomal Amphotericin B (AmBisome). Int J Antimicrob Agents, 2000; 16: 541–543.
  • Tollemar J, Ringden O, Tyden G. Liposomal ampho-tericin B (AmBisome) treatment in solid organ and bone mar-row transplant recipients: Efficacy and safety evaluation. Clin Transpl, 1990; 4: 167–175.
  • Tiphine M, Letscher-Bru V, Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl Infect Dis 1999; 1: 272–283.
  • Adler-Moore JP, Proffitt RT. Development, characterisa-tion, efficacy and mode of action of ambisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res, 1993; 3: 429–50.
  • Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother, 2002; 46: 828–833.
  • Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh T. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother, 2002; 46: 834–840.
  • Janknegt R, de Marie S, Bakker-Woundenberg IAJM, Crommelin DJA. Liposomal and lipid formulations of ampho-tericin B. Clinical pharmacokinetics. Clin Pharmacokinet, 1992; 23: 279–291.
  • Heinemann V, Bosse D, Jehn U, et al. Enhanced pul-monary accumulation of liposomal amphotericin B (AmBisome) in acute liver transplant failure. J Antimicrob Chemother, 1997; 40: 295–297.
  • Boswell GW, Buell D, Bekersky I. AmBisome (liposo-mal amphotericin B): a comparative review. J Clin Pharmacol, 1998; 38: 583–592.
  • Bekersky I, Borwell GW, Hiles R, Fielding RM, Buell DN, Walsh TJ. Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (ambisome): a 91-day study in rats. Pharm Res, 2000; 17: 1494-1502.
  • Matot I, Pizov R. Pulmonary extraction and accumula-tion of lipid formulations of amphotericin B. Crit Care Med, 2000; 18: 2528–2532.
  • Townsend W, Zutshi A, Bekersky I. Biodistribution of 4-r14c cholesterol-ambisome following a single intravenous administration to rats. Drug Metab Disp, 2001; 29: 681–685.
  • Collette N, van der Auwera P, Lopez AP, Heymans C, Meunier F. Tissue concentrations and bioactivity of ampho-tericin B in cancer patients treated with amphotericin B deoxycholate. Antimicrob Agents Chemother, 1989; 33: 362–368.
  • Collette N, van der Auwera P, Meunier F, Lambert C, Sculier JP, Coune A. Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. J Antimicrob Chemother, 1991; 27: 535–548.
  • Heinemann V, Bosse D, Jehn U, et al. Pharmacokinetics of liposomal amphotericin B (AmBisome) in critically ill patients. Antimicrob Agents Chemother, 1997; 41: 1275–1280.
  • Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs. Pharm Res, 1999; 16: 1694–1701.
  • Christiansen KJ, Bernard EM, Gold JW, Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis, 1985; 152: 1037–1043.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.